Literature DB >> 26712130

Thromboembolic events in patients with severe inherited fibrinogen deficiency.

Amihai Rottenstreich1, Avigal Lask2, Lilliana Schliamser3,4, Ariella Zivelin2, Uri Seligsohn2, Yosef Kalish5.   

Abstract

Inherited afibrinogenemia and hypofibrinogenemia are rare bleeding disorders characterized by markedly reduced levels of fibrinogen in blood. Thrombotic complications in these disorders have been rarely described. We performed a multicenter retrospective study and reviewed the occurrence of thrombotic complications among patients with inherited fibrinogen deficiency. Cases were identified during a review of medical records of all patients with inherited fibrinogen deficiency followed at three different university hospitals in Israel. Nine patients were included in this study: five were afibrinogenemic and four hypofibrinogenemic. There were seven thrombotic events, mostly venous, that occurred in four out of nine patients (44 %). All thrombotic events occurred in afibrinogenemic patients. Mean age at the time of thrombosis was 45 (range 28-61) years. Thrombophilic evaluation performed was negative in all cases. At the time of thrombosis in five out of seven (71.4 %) events, fibrinogen replacement therapy was concurrently given. Therapeutic approach was different among patients ranging from supportive therapy alone, antiplatelet agents and anticoagulant therapy with the concurrent administration of fibrinogen replacement therapy. This study discloses a high rate of thrombosis in patients with afibrinogenemia. Events were both venous and arterial and may be recurrent. Management is highly problematic due to the precarious balance between bleeding and thrombotic risk in these patients. Fibrinogen replacement therapy should be cautiously used in these patients as most thrombotic events followed the administration of fibrinogen replacement therapy. Larger cohorts are warranted to better characterize the best management strategy in these paradoxical events.

Entities:  

Keywords:  Afibrinogenemia; Deep vein thrombosis; Fibrinogen replacement therapy; Myocardial infarction; Renal vein thrombosis; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26712130     DOI: 10.1007/s11239-015-1325-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.

Authors:  H Ni; C V Denis; S Subbarao; J L Degen; T N Sato; R O Hynes; D D Wagner
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; J L Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Planned pregnancy and delivery in a patient with congenital afibrinogenaemia and heterozygous protein C deficiency.

Authors:  H Takahashi; K Wada; A Shibata
Journal:  Blood Coagul Fibrinolysis       Date:  1995-04       Impact factor: 1.276

Review 4.  Congenital afibrinogenemia.

Authors:  H al-Mondhiry; W C Ehmann
Journal:  Am J Hematol       Date:  1994-08       Impact factor: 10.047

Review 5.  Fibrinogen replacement therapy for congenital fibrinogen deficiency.

Authors:  L Bornikova; F Peyvandi; G Allen; J Bernstein; M J Manco-Johnson
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

Review 6.  Rare bleeding disorders: diagnosis and treatment.

Authors:  Roberta Palla; Flora Peyvandi; Amy D Shapiro
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

7.  How I use fibrinogen replacement therapy in acquired bleeding.

Authors:  Jerrold H Levy; Lawrence T Goodnough
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

Review 8.  Congenital fibrinogen disorders.

Authors:  Philippe de Moerloose; Marguerite Neerman-Arbez
Journal:  Semin Thromb Hemost       Date:  2009-07-13       Impact factor: 4.180

Review 9.  Thrombotic complications in patients with hereditary bleeding disorders.

Authors:  Massimo Franchini
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

10.  Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo- and afibrinogenemia.

Authors:  G Castaman; M Lunardi; L Rigo; V Mastroeni; E Bonoldi; F Rodeghiero
Journal:  Haemophilia       Date:  2009-03       Impact factor: 4.287

View more
  5 in total

1.  Identification of Two Novel Fibrinogen Bβ Chain Mutations in Two Slovak Families with Quantitative Fibrinogen Disorders.

Authors:  Tomas Simurda; Jana Zolkova; Zuzana Snahnicanova; Dusan Loderer; Ingrid Skornova; Juraj Sokol; Jan Hudecek; Jan Stasko; Zora Lasabova; Peter Kubisz
Journal:  Int J Mol Sci       Date:  2017-12-29       Impact factor: 5.923

Review 2.  Clinical Consequences and Molecular Bases of Low Fibrinogen Levels.

Authors:  Marguerite Neerman-Arbez; Alessandro Casini
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

Review 3.  Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.

Authors:  Tomas Simurda; Monika Brunclikova; Rosanna Asselta; Sonia Caccia; Jana Zolkova; Zuzana Kolkova; Dusan Loderer; Ingrid Skornova; Jan Hudecek; Zora Lasabova; Jan Stasko; Peter Kubisz
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

Review 4.  Extension of the Human Fibrinogen Database with Detailed Clinical Information-The αC-Connector Segment.

Authors:  Zofie Sovova; Klara Pecankova; Pavel Majek; Jiri Suttnar
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

5.  Clinical, biological, and genetic features in an afibrinogenemia patient series in Algeria.

Authors:  Soraya Hadjali-Saichi; Philippe de Mazancourt; Jacqueline Tapon-Bretaudière; Tristan Mirault; Kahina Guenounou; Issam Frigaa; Anne-Marie Fischer; Ouerdia Chafa; Dominique Helley
Journal:  Haemophilia       Date:  2022-04-30       Impact factor: 4.263

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.